AxAron.com
Title
Axaron Bioscience AG - mission is to be a leader in innovative CNS therapeutics
Description
Axaron Bioscience AG is a biotech company that aims to develop drugs which address the large-volume and fast growing neurodegenerative disorders market. The company has built an attractive portfolio of compounds focused on the treatment of stroke, Spinal Cord Injury (SCI), ALS (Amyotrophic Lateral Sclerosis) and Parkinson's disease. The most advanced drug candidate AX200 has already entered phase II stroke trials at the end of 2004. Another compound, AX201 is scheduled for phase II clinical trials for stroke in 2006. Based on its proprietary D FINE platform, Axaron is able to quickly identify and develop drugs with neuroprotective or neuroregenerative properties. This enables the company to generate a constant flow of new drug candidates.
Languages
English
Additional Information
Domain Resolution
This domain resolves to the following IP addresses:
- Bioinformatics
- Basf
- Lynx
- Biotechnologie
- Genomics
- Genome
- Functional Genomics
- Proteomics
- Biopharmaceutical
- Molecular Biology
- Genes
- Targets
- Target Identification
- Drug Safety
- Antibody
- Expression Profiling
- Gene Expression
- Cell Biology
- Microarray
- Cns
- Central Nervous System
- Zns
- Zentralnervensystem
- Als
- Amyotrophic Lateral Sclerosis
- Amyotrophe Lateralsklerose
- Lou Gehrig's Disease
- Parkinson
- Brain Trauma
- T Pa
- Neurology
- Neurological Disorders
- ALS
- BASF
- CNS
- LYNX
- T-PA
- ZNS